A retrospective chart review was carried out on 344 patients with systemic sclerosis (SSc) followed prospectively for the occurrence of pulmonary hypertension (PHT). Seventeen patients (4.9%) were found to have PHT. Eight patients had isolated PHT, while in nine PHT was associated with restrictive lung disease (RLD). The subset with RLD developed PHT earlier, but had longer survival than patients with isolated PHT. Patients with limited scleroderma tend to develop isolated PHT, while in those with diifuse disease PHT is associated with RLD. Irrespective of disease type, PHT in SSc has an extremely poor prognosis with a median survival of 12 months following diagnosis.
PULMONARY hypertension (PHT) occurs as a manifestation of systemic sclerosis (SSc) and can be due primarily to pulmonary vascular abnormalities, or secondary to interstitial lung or cardiac involvement. The former is usually found in patients with limited scleroderma and minimal or no pulmonary fibrosis [1, 2] . In contrast, patients with diffuse scleroderma may develop PHT on the basis of severe pulmonary fibrosis, but this is uncommon [3] . The frequency of PHT in SSc is uncertain, but was clinically detectable in 9% of patients in a large prospectively followed cohort [2] ; in another study, 33% were diagnosed on right heart catheterization [1] and autopsy evidence was found in 65% of CREST patients [4] . Certain genetic markers, in particular HLA DRW6 and DRW52, have previously been described in association with PHT in SSc [5] .
In a previous study, we found pulmonary disease to be the most frequent cause of death in SSc [6] . This accounted for 16 deaths amongst a cohort of 237 patients (7%) and in 10 patients this was due to PHT. In the present study, the clinical and laboratory features, and HLA distribution of 17 SSc patients with PHT were analysed.
PATIENTS AND METHODS
Between 1978 and December 1994, 344 patients with SSc (140 with diffuse and 204 with limited scleroderma) were followed prospectively in the scleroderma clinic at the Wellesley Hospital, and 17 (4.9%) were found to have PHT. All fulfilled the American College of Rheumatology (formerly the American Rheumatism Association) classification criteria for SSc [7] . Patients were classified as having limited scleroderma when definite skin thickening was confined to the face and limbs; in diffuse scleroderma, the trunk was also involved. Disease duration was calculated from the time of diagnosis of SSc to the last contact with the patient or death. Visceral organ involvement was according to Medsger [8] , with modifications [9] .
Pulmonary hypertension was diagnosed according to the presence of one of the following three criteria: (1) a resting mean pulmonary artery pressure (MPAP) of 25 mmHg with a pulmonary capillary wedge pressure of < 12 mmHg on right heart catheterization; (2) a right ventricular systolic pressure of > 35 mmHg estimated by Doppler echocardiography; (3) echocardiographic evidence of right ventricular dilatation, pulmonary and/or tricuspid regurgitation or paradoxical interventricular septal motion [10] . Patients with primary cardiac disease which could result in secondary PHT were excluded.
All patients had a chest X-ray, 12-lead electrocardiogram (ECG), pulmonary function tests and echocardiography (with Doppler in 13 patients) carried out at the onset of cardiopulmonary symptoms. Four patients who underwent M mode and 2D echocardiography (without Doppler) also had right heart catheterization. Pulmonary function studies included spirometry [forced vital capacity (FVC)], body plethysmography-lung volume determination [total lung capacity (TLC)]; and lung diffusion-single breath carbon monoxide diffusion capacity (DLCO) with correction for haemoglobin. In all instances, the results were expressed as a percentage of the predicted normal value [11, 12] . A diagnosis of restrictive lung disease (RLD) was based on the presence of TLC or FVC of <80% of the predicted normal value with a forced expiratory volume at 1 s to FVC (FEV,/FVC) ratio of >70% of predicted normal.
HLA analyses were performed on nine of the patients with PHT by the microcytotoxicity test. Lymphocytes were separated from peripheral blood by Ficoll-Hypaque centrifugation. B and T cells were further isolated by passage over nylon wool columns [13] . Tissue-typing trays from One-Lambda (Los Angeles, CA, USA) and the Canadian Red Cross National Reference Laboratory (Toronto, Ontario, © 1996 British Society for Rheumatology 
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Statistical analysis
The Kaplan-Meier method was used to calculate estimates of survival probabilities. Analyses were performed on SAS PC software and included descriptive statistics and Student's /-test to test for differences between the subsets with and without RLD.
RESULTS
The demographic data on the 17 patients with SSc and PHT are shown in Table I . The majority were Caucasian (94%), women (88%) and had limited scleroderma (65%). None were lost to follow-up. Two patients were smokers and another had previously smoked. One of the three subsequently developed RLD, but all three had normal FVC, TLC and FEV|/FVC ratio on initial pulmonary function testing. The overall prevalence of PHT in our SSc population was 4.9%, and the frequency in the subsets with diffuse and limited scleroderma was 4.3 and 5.4%, respectively. Table II shows the clinical manifestations noted at any time during the disease course and co-morbid conditions in this subset of patients. Dyspnoea was the presenting symptom of PHT in all 17 cases and was invariably severe (grade III: present after walking < 100 yards at a slow pace; grade IV: on dressing, talking or at rest) in 16 patients at diagnosis. All 17 patients had accentuation of the pulmonary second sound at the time of diagnosis of PHT; a parasternal heave was observed in two patients. Basal end-inspiratory crackles were present in 11 patients (65%), more frequently in the group with RLD (78%) than in those without (50%). Otherwise the nine patients with RLD did not differ from the eight patients without RLD in terms of presenting symptoms or organ involvement. Three patients (18%) had a malignancy. Carcinoma of the breast and thyroid had preceded, while carcinoma of the uterus had developed subsequent to the diagnosis of SSc. Antinuclear antibodies were present in 12 of 15 (80%).patients who had this test done (using rat liver slices as substrate).
The results of cardiological investigations in these patients are shown in Table III . Pulmonary hypertension was confirmed in four patients by right heart catheterization and in 13 patients by echocardiography with Doppler. Echocardiography revealed abnormalities characteristic of PHT in all 17 patients. The ECG was abnormal in 15 patients (83%). Eight patients (47%) had chest X-ray evidence of bibasilar pulmonary fibrosis.
All 17 of our patients had a reduced DLCO at the time of diagnosis of PHT. In 12 (71%) cases, the DLCO was <60% of predicted normal and in 10 (59%) cases the DLCO was <50% of predicted normal. Of the 17 patients with PHT, nine met the criteria for RLD. In seven, the TLC and/or FVC was between 50 and 75%, while in two this was <50% of predicted normal. Table IV shows a comparison of the characteristics between patients with and without RLD. Patients with RLD had a significantly greater reduction in FVC and TLC, and a greater frequency of pulmonary fibrosis on chest X-ray. The extent of the pulmonary fibrosis in these patients was quite variable (from normal lung fields to widespread changes). The Right heart catheterization (n * mean DLCO and pulmonary artery (or right ventricular systolic) pressures were not significantly different. The subset with RLD developed PHT significantly earlier in the course of SSc, but had longer survival after diagnosis of PHT than those without RLD. The mean duration between the diagnosis of SSc and PHT for the 17 patients was 3.3 ± 3.9 yr.
Tissue typing carried out in nine patients from this study and 33 SSc patients without PHT showed no significant differences in frequency of the various HLA antigens tested for.
Prednisone (mean dose 10 mg/day for a mean duration of 6 months) and D-penicillamine (500-750 mg/day for a mean duration of 11 months) were administered to three patients with RLD without improvement of their VC, TLC or DLCO, or symptoms. Monthly i.v. pulse cyclophosphamide was given to one patient with RLD for six doses. Although the pulmonary function abnormalities stabilized, PHT developed soon afterwards. All patients received home oxygen. All patients with Raynaud's phenomenon were treated with nifedipine (30-90 mg/day). Intravenous prostaglandin El, and oral hydralazine, nifedipine and captopril, administered at the time of cardiac catheterization in four patients, did not significantly reduce the pulmonary artery pressure.
Fifteen of the 17 patients (88%) have died: 14 from heart failure (cor pulmonale secondary to PHT) and one from upper gastrointestinal bleeding secondary to non-steroidal anti-inflammatory drugs. The median survival after diagnosis of PHT was 12 months (95% confidence interval 4-40). Figure 1 shows the Kaplan-Meier survival curve for the 17 patients with pulmonary hypertension compared to a subset with lung involvement (of all categories) and another without major organ involvement (heart, lung or kidney) from the same clinic population [6] . New onset of systemic hypertension (> 140/90 mmHg), in the absence of renal disease, was associated with the onset of PHT in five patients.
DISCUSSION
In the present study, we analysed the clinical and laboratory features of 17 SSc patients with PHT. The frequency of PHT amongst 344 SSc patients followed prospectively at this centre was 4.9%, which is less than the prevalence of 9% reported by Stupi et al. [2] . Ungerer et al. [l] reported a prevalence of 33%, but all of their 49 patients had right heart catheterization and those with borderline pressures were also included. Sackner et al. [14] noted that one-half of their patients with PHT only had evidence of this complication on catheter studies. Prevalence figures for PHT in SSc are therefore heavily influenced by the extent of the investigations carried out.
Our findings concur with previous observations in that PHT was found more frequently in those with limited scleroderma [1] [2] [3] [4] . However, patients with diffuse disease are also at risk, especially in the presence of restricted lung disease, but rarely on the basis of severe pulmonary fibrosis alone [3] . Patients with SSc in this study were also separated into groups with and without RLD depending on the presence or absence of a decrease in lung volume (TLC and/or FVQ. As expected, the majority of those with RLD had radiological evidence of pulmonary fibrosis, and approximately equal numbers had diffuse and limited skin thickening. In contrast, the majority of those without RLD had limited scleroderma and these patients fit into the category of isolated PHT described by Stupi et al. [2] . Although high-resolution CT scanning is more sensitive than a chest X-ray for diagnosing early pulmonary fibrosis, this procedure was not routinely carried out in our patients. Smoking has been reported to be associated with more severe RLD in SSc, but was not a significant factor in this study [3] .
It is of interest that PHT developed significantly earlier in the course of SSc in those with RLD than in patients without RLD. Steen et al. [15] also found severe RLD (as well as primary cardiac involvement) to be associated with disease of short duration. These patients appear to develop pulmonary manifestations early in the course of their illness, with the greatest rate of loss of FVC occurring during the first 2 yr. After diagnosis of PHT, however, our patients with RLD (compared to those without) survived longer. The difference was not statistically significant, probably because of the small numbers of patients.
Pulmonary vascular disease with concentric intimal fibrosis and smooth muscle hyperplasia, predominantly of the small and medium-sized arteries, is probably the underlying cause of PHT in the subset without RLD [4, 16] . These patients are characterized by the presence of an isolated diffusion defect with absent or minimal pulmonary fibrosis. Thirty of the 59 cases of PHT reported by Stupi et al. [2] were in this category and described as having isolated PHT. Patients at the greatest risk of developing this form of PHT are those with the CREST variant of SSc and correspond to our subset with limited scleroderma [1] [2] [3] . Of the nine patients in our study with isolated PHT, 78% had limited scleroderma. Pulmonary vascular hyperplasia possibly plays a significant role in the pathogenesis of PHT in our subset of patients with RLD as well since the majority of them had pulmonary fibrosis of only mild severity.
It has been suggested that certain HLA specificities are associated with subsets of SSc [17] . All nine patients from this study who had HLA analysis showed the presence of DR52. Data on these patients were previously reported as part of a larger study which demonstrated associations between this antigen and diffuse scleroderma, PHT and adverse prognosis [5] . An association between DR52a, a subtype of DR52, and pulmonary fibrosis has also been reported [18] .
Once diagnosed, PHT in patients with SSc invariably runs a rapid downhill course with extremely poor long-term survival. The median survival after diagnosis of PHT in our series was only 12 months. Individual patients did survive up to 67 months and those with longer survival had RLD. These findings confirm the grim prognosis which has previously been reported. The 2 yr cumulative survival rate for 30 patients with PHT (and CREST) studied by Stupi et al. [2] was 40%, which is worse than their experience with hypertensive renal crisis.
A severe reduction in diffusion capacity appears to be a sensitive predictor for PHT as well as an adverse prognostic factor [1, 19, 20] . Peters-Golden et al. [19] noted a markedly reduced survival rate when the DLCO was <40% of predicted normal, although the presence or absence of PHT in their patients was not known. While all of our patients had a reduced DLCO at diagnosis of PHT, four (two with and two without RLD) had a reduced DLCO up to 48 months prior to diagnosis of PHT. In three this was < 60% and in one <50% of predicted normal. While changes in pulmonary tests over time are quite variable [19, [21] [22] [23] , a severe (isolated) reduction in DLCO (<55% of predicted) or increased FVC/DLCO ratio (> 1.4) were found to be excellent predictors of PHT [19, 20] .
As has been the experience of others [2] , we did not find any (i.v. or oral) therapy which was effective either in reducing the pulmonary artery pressure or altering the progressive nature of PHT. Oxygen therapy, however, is effective in improving the level of dyspnoea and function, and has been found to decrease pulmonary vascular resistance in these patients [24] . Studies with different vasodilators have produced variable results. While captopril and nifedipine were shown to reduce pulmonary vascular resistance in some patients, the pulmonary artery pressure invariably remained elevated in those with severe PHT [25] [26] [27] . Their ability to influence the progressive downhill course of PHT is doubtful, especially since pulmonary function, including diffusion capacity, was not improved by iloprost, a potent vasodilator [28] . In another study, iloprost was infused continuously for 30 weeks in five patients with PHT (three in association with SSc and two with the antiphospholipid syndrome) [29] . While both functional class and exercise tolerance improved in all patients, the haemodynamic response was variable and there was no significant improvement in pulmonary artery O 2 saturation (the best predictor of survival in PHT). Nifedipine, however, was effective in improving the DLCO in SSc patients without PHT [30] . This suggests that nifedipine may be useful prophylactically in patients with a very low diffusion capacity and at risk for developing PHT.
